Phase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity
/in Clinical Trial, Non-Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 44/2026 November 1, 2026
- UPDATE: JNJ-6143 RIPTAC Advances to Randomized Phase 3 Trial With Overall Survival Endpoint October 31, 2026
- Phase 1/2 Trial Will Investigate STAR0602 Plus Nivolumab in Metastatic Prostate Cancer October 31, 2026
- TIDE-PC Phase 2 Trial Will Test Testosterone-Guided ADT De-Escalation in Metastatic Prostate Cancer October 31, 2026